|
The Cochrane Collaboration
Cochrane Reviews |
| Explore | New + Updated | Other languages |
|
 |
Danazol for uterine fibroidsKe Lq, Yang K, Li J, Li C-M
Bookmark this:
     more ...
SummaryDanazol for treatment of women with symptoms caused by uterine fibroidsThere is no evidence from randomised controlled trials demonstrating that the benefits of danazol outweigh its risks in treating uterine fibroids. Danazol is a synthetic isoxazole derivative chemically related to 17-ethinyl testosterone which creates a high androgen and low estrogen environment, resulting in the wasting of endometrium and shrinkage of fibroids. Despite its benefits, various undesirable side effects have also been reported. These include acne, hirsutism (excess hair in females with an adult male pattern of distribution), weight gain, irritability, musculoskeletal pain, hot flushes, and breast atrophy, which many women may not tolerate. The review found no evidence demonstrating that the benefits of danazol which outweighed the risks in treating uterine fibroids.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2010 Issue 1, Copyright © 2010 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This version first published online:
July 08. 2009 AbstractBackgroundUterine fibroids (myomas, fibromyomas, leiomyomas) are the most common benign tumours of the female genital tract. Danazol, a synthetic isoxazole derivative chemically related to 17-ethinyl testosterone, has been used for many years for the treatment of women with uterine fibroids. ObjectivesTo evaluate the effectiveness and safety of danazol in women with uterine fibroids. Search strategyWe searched the Cochrane Menstrual Disorders and Subfertility Review Group Specialised Register; Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 4); MEDLINE; EMBASE; Chinese Biomedical Disc; and the China National Knowledge Infrastructure for relevant trials (to December 2008). Attempts were made to identify trials from references in published studies. We also searched for ongoing trials in the five major clinical trials registries. Selection criteriaRandomised controlled trials of danazol versus placebo or any other medical therapy in women with uterine fibroids confirmed by medical procedures, regardless of the women's symptoms or age. Women with malignancies were excluded. Data collection and analysisData extraction and risk of bias assessment were not been performed because there were no identified studies. Main resultsWe did not identify any studies which met our full inclusion criteria. Authors' conclusionsThere is no reliable evidence available from randomised controlled trials regarding the benefits and or harms of the use of danazol for treating uterine fibroids. |